Prescribing melatonin to children and young people under the age of 17 in England has risen by 245% over the past nine years[1]. In the first quarter of 2024/2025, 117,093 patients received melatonin, compared to 33,926 patients in the first quarter of 2015/2016[1]. This increase is related to a decrease in the prescription of other insomnia drugs, such as Z-drugs and benzodiazepines[1]. The number of children prescribed zopiclone fell from 631 to 146 and diazepam from 2,833 to 1,627 over the same period[1]. Melatonin was previously mainly prescribed off-label, but now there is a licensed option for children with insomnia[1]. In the US, the number of melatonin poisonings in children has increased by 530% in the last 10 years, mostly unintentionally in children under the age of 5[2]. Largest increase seen during pandemic, with melatonin sales at $821 million in 2020[2].